阿苯达唑市场调查分析  

Market Research and Analysis of Albendazole

作　　者：朱振国[1] 郑荣远[1] 杨学志[1] 殷为勇[1] 

机构地区：[1]温州医学院附属第一医院神经科,温州市325000

出　　处：《中国药房》2009年第1期18-21,共4页China Pharmacy

基　　金：国家食品药品监督管理局药品评价中心资助项目

摘　　要：目的:为临床合理、安全应用阿苯达唑提供参考。方法:通过搜索引擎及国内、外各医药网站、数据库,对阿苯达唑的研发情况、市场信息、适应证等情况进行分析。结果与结论:目前阿苯达唑有片剂、胶囊剂、颗粒剂、口服液、糖浆剂5种剂型;近几年其在国内销售额基本列居抗寄生虫药的前3位,生产厂家国内达39家;可用于治疗21种人体寄生虫病。阿苯达唑临床使用广泛,但是引发少见的脑炎综合征、过敏性休克等严重不良反应隐藏着治疗风险,须加强管理。OBJECTIVE： To provide information for clinical rational and safe use of albendazole. METHODS： The medical database and network both at home and abroad were searched and the data regarding the research and development, the market information and indications of albendazole were analyzed. RESULTS ＆ CONCLUSIONS： 5 dosage forms of albendazole are available in the market： tablets, capsules, granules, oral liquid, and syrup. The sales amount of albendazole in recent years dominated the first 3 places in domestic antiparasites market. There are a total of 39 domestic manufactures for albendazole, which can be used to treat 21 kinds of human parasitosis. Its clinical application is widespread. However, severe adverse drug reactions such as the rare encephalitis syndrome and allergic shock etc induced by albendazole pose hidden risks for treatment; therefore, management on its use should be strengthened.

关 键 词：阿苯达唑 研发概况 市场信息 临床应用 

分 类 号：R978[医药卫生—药品]